JPMorgan Double Downgrades Dova Pharmaceuticals Inc (DOVA) to Underweight
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/25/2026
- Wall Street closes lower to end rocky week
- Meta's capital-raising plans expose a major weakness in the AI boom
- Oil prices jump $3 on Houthi attacks, oil spill, highest settlement since April
- BofA flags further downside risk for stocks, yields and dollar
- SpaceX cell-site ambitions lift tower stocks and weigh on carriers
Tweet
Share
E-mailGet Alerts DOVA Hot Sheet
Price: $28.04 --0%
Rating Summary:
4 Buy, 5 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 11 | Down: 14 | New: 15
Rating Summary:
4 Buy, 5 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 11 | Down: 14 | New: 15
Join SI Premium – FREE
JPMorgan analyst Anupam Rama downgraded Dova Pharmaceuticals Inc (NASDAQ: DOVA) from Overweight to Underweight with a price target of $20.00 (from $34.00).
The analyst adjusts recommendations for US SMid names following the recent Healthcare Conference.
For an analyst ratings summary and ratings history on Dova Pharmaceuticals Inc click here. For more ratings news on Dova Pharmaceuticals Inc click here.
Shares of Dova Pharmaceuticals Inc closed at $7.78 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- CG Power & Industrial Solutions (CGPOWER:IN) PT Raised to INR944 at JPMorgan
- Dr. Reddy\'s Laboratories (DRRD:IN) (RDY) PT Raised to INR1,220 at Kotak
- Hindustan Petroleum (HPCL:IN) PT Lowered to INR350 at Kotak
Create E-mail Alert Related Categories
Analyst PT Change, Downgrades, Hot DowngradesRelated Entities
JPMorganSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
